No clinical trials have tested ozone therapy specifically for PTSD. The rationale relies on ozone’s anti-inflammatory and neuromodulatory activity, but the evidence trail ends at general mechanism studies and extrapolation from other conditions. By contrast, HBOT has an actual randomized trial in treatment-resistant PTSD: 60 sessions produced significant symptom improvement versus sham, with a large effect size of 1.64 that persisted at two years (Doenyas-Barak et al., 2022).
The short version: ozone therapy for PTSD has zero published human trials. If you want an oxygen-based option with real clinical data, that is HBOT, not ozone.
How does PTSD change the brain?
PTSD involves measurable changes in brain structure and function. Neuroimaging consistently shows abnormalities in three regions (Pitman et al., 2012):
- Amygdala. Hyperactive in PTSD, driving exaggerated fear responses and hypervigilance.
- Prefrontal cortex. Underactive, impairing the ability to regulate emotion and separate past threats from present safety.
- Hippocampus. Reduced volume, affecting memory processing and the ability to file traumatic memories as past rather than ongoing.
Neuroinflammation is part of the picture. PTSD patients show elevated inflammatory markers (CRP, IL-6, TNF-alpha), activated microglia, and increased blood-brain barrier permeability. This inflammatory state impairs neuroplasticity and may hinder natural recovery from trauma (Pitman et al., 2012).
Could ozone therapy help PTSD?
In theory, yes; in practice, this has never been tested. Ozone therapy’s proposed relevance to PTSD rests on mechanisms documented for ozone in general settings, none of which have been studied in PTSD patients.
Proposed ozone mechanisms and their PTSD relevance
| Mechanism | What ozone does | PTSD relevance | Evidence level |
|---|---|---|---|
| Anti-inflammatory | Modulates NF-kB, activates Nrf2, lowers pro-inflammatory cytokines | Neuroinflammation is elevated in PTSD | Established for ozone, not tested in PTSD |
| Improved oxygenation | Increases oxygen delivery to tissue via 2,3-DPG | Brain hypoperfusion is observed in PTSD | Established for ozone, not tested in PTSD |
| Oxidative preconditioning | Trains antioxidant systems to handle oxidative stress | Oxidative stress contributes to neuronal damage in PTSD | Preclinical only |
| Mitochondrial support | May improve mitochondrial function and energy production | Mitochondrial dysfunction is linked to anxiety and PTSD | Preclinical only |
Each mechanism is documented for ozone therapy in general contexts (Bocci and Valacchi, 2015; Sagai and Bocci, 2011). The problem is that none have been tested in PTSD patients. The leap from “ozone reduces inflammation” to “ozone treats PTSD” requires clinical evidence that does not exist.
Why is there no evidence for ozone and PTSD?
Several factors explain the empty research record:
- PTSD research funding flows to psychotherapy, pharmaceuticals, and more established biological interventions (HBOT, ketamine, MDMA-assisted therapy, TMS).
- Ozone therapy lacks the institutional and commercial backing needed to fund expensive psychiatric trials.
- The regulatory picture around ozone therapy complicates IRB approval for psychiatric use.
- HBOT, which shares some mechanistic overlap, is already being studied for PTSD and absorbs the research attention that might otherwise go to ozone.
Is HBOT or ozone therapy better for PTSD?
For an oxygen-based approach to PTSD, HBOT has a substantially stronger evidence base than ozone. Our overview of the hyperbaric chamber for PTSD covers this in depth.
Ozone therapy versus HBOT for PTSD
| Factor | Ozone therapy | HBOT |
|---|---|---|
| Published PTSD trials | None | Randomized controlled trial with 2-year follow-up |
| Neuroimaging evidence | None for PTSD | fMRI and DTI showing improved brain microstructure and function |
| Long-term follow-up | None | Benefits persisted at 2 years with improved social functioning |
| Cost per session | $100-300 | $200-400 |
| Typical protocol | No established protocol | 40-60 sessions (based on trial data) |
The Doenyas-Barak trial is the anchor. Veterans with treatment-resistant PTSD received 60 daily HBOT sessions, and their CAPS-5 scores (the standard PTSD measure) improved significantly with a large effect size of 1.64, alongside imaging changes in the prefrontal cortex, hippocampus, and insula (Doenyas-Barak et al., 2022). At two-year follow-up, improvements held: working rates rose from 41% to 73%, partnership rates from 46% to 77%, and benzodiazepine and cannabis use fell (Doenyas-Barak et al., 2023).
What should you realistically expect?
Ozone therapy sessions typically cost $100 to $300 each. With no established PTSD protocol, practitioners may recommend anywhere from 10 to 30 sessions, so out-of-pocket costs range widely, and insurance does not cover it. For comparison, HBOT for PTSD runs $200 to $400 per session across 40 to 60 sessions in the evidence-based protocols.
Anyone considering ozone therapy for PTSD should be clear-eyed: there is no clinical evidence it works for this condition, and it should never replace evidence-based care. That care includes trauma-focused cognitive behavioral therapy, eye movement desensitization and reprocessing (EMDR), prolonged exposure therapy, and FDA-approved medications (sertraline, paroxetine). Ozone therapy for other conditions is covered in our ozone therapy for depression and ozone therapy protocols guides.
Key terms
| Term | Meaning |
|---|---|
| CAPS-5 | Clinician-Administered PTSD Scale, the standard structured interview for measuring PTSD severity. |
| Neuroinflammation | Inflammation of nervous system tissue, involving activated microglia and inflammatory cytokines. |
| Effect size | A standardized measure of how large a treatment’s impact is; 1.64 is considered large. |
The bottom line
Ozone therapy for PTSD is a theoretical application with zero clinical evidence. The biological rationale is plausible but unproven, and “could theoretically help” is not the same as “has been shown to help.” For an oxygen-based PTSD treatment with real data, HBOT has randomized-trial evidence with neuroimaging confirmation and long-term follow-up. For PTSD in general, trauma-focused psychotherapy and FDA-approved medications remain the standard of care.
Sources
- Doenyas-Barak K, Catalogna M, Kutz I, et al. Hyperbaric oxygen therapy improves symptoms, brain’s microstructure and functionality in veterans with treatment resistant post-traumatic stress disorder: a prospective, randomized, controlled trial. PLoS ONE. 2022;17(2):e0264161. doi:10.1371/journal.pone.0264161
- Doenyas-Barak K, Catalogna M, Kutz I, et al. Hyperbaric oxygen therapy for veterans with treatment-resistant PTSD: a longitudinal follow-up study. Military Medicine. 2023;188(7-8):e2227-e2234. doi:10.1093/milmed/usac360
- Pitman RK, Rasmusson AM, Koenen KC, et al. Biological studies of post-traumatic stress disorder. Nature Reviews Neuroscience. 2012;13(11):769-787. doi:10.1038/nrn3339
- Bocci V, Valacchi G. Nrf2 activation as target to implement therapeutic treatments. Frontiers in Chemistry. 2015;3:4. doi:10.3389/fchem.2015.00004
- Sagai M, Bocci V. Mechanisms of action involved in ozone therapy: is healing induced via a mild oxidative stress? Medical Gas Research. 2011;1(1):29. doi:10.1186/2045-9912-1-29
Medical Disclaimer
The content on BaricBoost.com is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Author
Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.
